🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

InventisBio clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with InventisBio as lead sponsor. Synced 26 Sep 2026
14Current trials
8Recruiting now
6Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

InventisBio is the lead sponsor of 14 current clinical trials in our China and USA registers. 8 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are D-2570, D-1553 and D-0502. The most-studied condition is Plaque Psoriasis.

ClinicalTrials.gov trials by status

  • Recruiting857%
  • Not yet open17%
  • Active, closed536%

Trials by phase

  • Phase 2536%
  • Phase 1429%
  • Phase 3321%
  • Phase 1/2214%
01

Clinical trials sponsored by InventisBio

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
NCT07326813 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Phase 3 Recruiting 2026-01 China
A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
NCT07715149 · ClinicalTrials.gov ↗ · Healthy Adult Participants, Hepatic Impairment (HI)
Drug: D-2570
Phase 1 Recruiting 2026-07 China
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
NCT07315061 · ClinicalTrials.gov ↗ · PsA (Psoriatic Arthritis)
Drug: D-2570
Phase 2 Recruiting 2026-01 China
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885 · ClinicalTrials.gov ↗ · Psoriasis
Drug: D-2570
Phase 2 Recruiting 2026-06 USA
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
NCT07130604 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: D-2570
Phase 3 Recruiting 2025-09 China
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 3 Recruiting 2022-09 China
Study of D-2570 in Subjects With Non-Segmental Vitiligo
NCT07625891 · ClinicalTrials.gov ↗ · Vitiligo, Non-Segmental Vitiligo (NSV)
Phase 2 Recruiting 2026-06 China
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT07311200 · ClinicalTrials.gov ↗ · Active Systemic Lupus Erythematosus
Drug: D-2570
Phase 2 Recruiting 2026-02 China
The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.
NCT07715175 · ClinicalTrials.gov ↗ · Renal Impairment
Drug: D-2570
Phase 1 Not yet open 2026-08 China
Healthy Volunteer Study
NCT07270783 · Healthy Volunteer
Drug: D-2570
Phase 1 Active, closed 2025-12 USA
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
NCT05379946 · ClinicalTrials.gov ↗ · Solid Tumor
Drugs: D-1553, IN10018
Phase 1/2 Active, closed 2022-10 China
Study to Evaluate D-1553 in Subjects With Solid Tumors
NCT04585035 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, NSCLC, CRC
Drug: D-1553
Phase 1/2 Active, closed 2020-10 USA
Mass Balance Study of [14C] D-2570
NCT07411742 · ClinicalTrials.gov ↗ · Mass Balance Study
Phase 1 Active, closed 2026-03 China
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT07035041 · ClinicalTrials.gov ↗ · UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis
Phase 2 Active, closed 2025-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in InventisBio trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in InventisBio trials

18 conditions
Plaque Psoriasis2Healthy Volunteer1Psoriasis1Solid Tumor, Adult1NSCLC1CRC1Solid Tumor1Healthy Adult Participants1Hepatic Impairment (HI)1PsA (Psoriatic Arthritis)1Mass Balance Study1UC - Ulcerative Colitis1Moderately to Severely Active Ulcerative Colitis1Renal Impairment1Breast Cancer1Vitiligo1Non-Segmental Vitiligo (NSV)1Active Systemic Lupus Erythematosus1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China117
Clinical trials in USA31

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Plaque Psoriasis

SponsorTrials
Oruka Therapeutics4
Alumis2

Sponsors with the most current trials registered for this condition.

06

Questions about InventisBio trials

How many clinical trials does InventisBio sponsor?

InventisBio is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are InventisBio trials recruiting?

Yes. 8 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is InventisBio testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are D-2570 (8), D-1553 (2), D-0502 (1), Deucravacitinib (1) and Fulvestrant (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.